Skip to main content

and
  1. No Access

    Article

    Rechallenge of docetaxel combined with epirubicin given on a weekly schedule in advanced castration-resistant prostate cancer patients previously exposed to docetaxel and abiraterone acetate: a single-institution experience

    The aim of this paper was to evaluate the activity and tolerability of weekly docetaxel (D) combined with weekly epirubicin (EPI) in patients with advanced castrate-resistant prostate cancer (CRPC) previously ...

    R. Petrioli, G. Roviello, A. I. Fiaschi, L. Laera, Salvatora T. Miano in Medical Oncology (2015)